The strong imaging/dosimetry data and differentiated safety profile (especially salivary gland sparing vs PSMA agents) position AKY-2519 as a potential best-in-class B7-H3 radioconjugate. Monitor the May 27 conference call for additional color on target lesion dosimetry and competitive positioning. Key catalysts ahead: initiation of second Phase 1b trial (H2 2026), preliminary mCRPC Phase 1b data (2027), and AKY-1189 Phase 1b data (Q1 2027).
Price Chart
Executive Summary
Aktis reported first-in-human clinical imaging and dosimetry data for AKY-2519, a B7-H3-targeted miniprotein radioconjugate, at ASCO 2026. The data across multiple solid tumors (mCRPC, NSCLC, SCLC, colorectal) showed robust tumor uptake, low normal tissue exposure (especially salivary glands), and a wide therapeutic index, supporting advancement to Phase 1b trials. The favorable imaging profile versus approved PSMA agents and differentiated safety signals are a positive catalyst for the clinical-stage radiopharmaceutical pipeline.
Key Facts
- AKY-2519 demonstrated robust tumor uptake and retention across mCRPC, NSCLC, SCLC, and rectal cancer, with prostate SUVmax 33.9–37.4.
- Predicted absorbed doses to critical normal tissues were favorable: bone marrow 0.04 GyRBE=5/MBq, salivary glands 0.13 GyRBE=5/MBq – lower than approved radiopharmaceuticals.
- No adverse events or infusion-related reactions reported in either assessment (n=16 mCRPC; n=18 multiple solid tumors).
- Two posters presented at ASCO 2026 (abstracts #3097 and #3098); data informed design of ongoing and planned Phase 1b trials in mCRPC and other B7-H3 expressing tumors.
- Company expects to initiate a second Phase 1b trial in other B7-H3 expressing solid tumors in H2 2026; preliminary data from mCRPC Phase 1b anticipated in 2027.
- AKY-2519 is the second clinical-stage program from Aktis' proprietary miniprotein radioconjugate platform; lead program AKY-1189 (Nectin-4) also in Phase 1b with data expected Q1 2027.
Financial Impact
No financial data disclosed; catalyst is clinical data readout supporting pipeline advancement for a $1.1B market cap clinical-stage biotech
Risk Factors
- AKY-2519 is still in early Phase 1b; pivotal efficacy/safety data are not yet available, and early-stage biotech assets carry high failure risk.
- Competition in radiopharmaceuticals is intensifying (Pluvicto, other B7-H3 targeting agents), and AKY-2519 may not achieve commercial differentiation in larger trials.
- Company has no approved products and relies on capital markets; future dilution risk exists given a ~$1.1B market cap and clinical-stage pipeline.
- Historical reports on AKTS show negative average T+5 and T+20 returns, suggesting market skepticism toward prior catalysts — this readout is more substantial but risk of disappointment remains.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299806 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $24.72 $22.41 | ▼ −9.34% | ▼ −7.37% | $18.11 (−26.74%) |
Jul 10, 2026 12w ago | Insider Cluster | $27.88 $24.13 | ▼ −13.45% | ▼ −15.88% | $18.11 (−35.04%) |
May 21, 2026 19w ago | Press Release | $20.34 $24.48 | ▲ +20.35% | ▲ +21.77% | $18.11 (−10.96%) |
May 11, 2026 20w ago | 8-K | $19.73 $18.58 | ▼ −5.83% | ▼ −4.10% | $18.11 (−8.21%) |
Apr 21, 2026 23w ago | Press Release | $22.00 $18.50 | ▼ −15.91% | ▼ −19.07% | $18.11 (−17.68%) |
Mar 30, 2026 26w ago | Press Release | $17.89 $18.87 | ▲ +5.48% | ▼ −3.94% | $18.11 (+1.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access